These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11194239)

  • 1. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
    Grover SA; Coupal L; Zowall H; Alexander CM; Weiss TW; Gomes DR
    Diabetes Care; 2001 Jan; 24(1):45-50. PubMed ID: 11194239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?
    Grover SA; Coupal L; Zowall H; Dorais M
    Circulation; 2000 Aug; 102(7):722-7. PubMed ID: 10942738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
    Grover S; Coupal L; Lowensteyn I
    Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease.
    Lowensteyn I; Coupal L; Zowall H; Grover SA
    J Cardiopulm Rehabil; 2000; 20(3):147-55. PubMed ID: 10860196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention.
    Grover SA; Paquet S; Levinton C; Coupal L; Zowall H
    Arch Intern Med; 1998 Mar; 158(6):655-62. PubMed ID: 9521231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.
    Herman WH; Alexander CM; Cook JR; Boccuzzi SJ; Musliner TA; Pedersen TR; Kjekshus J; Pyörälä K
    Diabetes Care; 1999 Nov; 22(11):1771-8. PubMed ID: 10546006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
    Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
    Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
    Kumar R; Tonkin A; Liew D; Zomer E
    Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
    Amirsadri M; Hassani A
    Daru; 2015 Dec; 23():56. PubMed ID: 26717884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
    Grover SA; Coupal L; Lowensteyn I
    Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
    Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
    Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor.
    Grover SA; Coupal L; Zowall H; Weiss TW; Alexander CM
    Am J Med; 2003 Aug; 115(2):122-8. PubMed ID: 12893398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.